Clinical trial
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic…
NCT00283751 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00283751 |
|---|---|
| Title | Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes |
| Official title | Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | insulin detemir, insulin glargine |
| Enrollment | 583 |
| Start date | Mar 1, 2003 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jan 30, 2006 |
| Last update posted | Jan 27, 2017 |
| Countries | Austria, Belgium, France, Germany, Ireland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: